Psychiatrists urge UK to reclassify psychedelics for research
The Royal College of Psychiatrists urges the UK government to reclassify MDMA and psilocybin from Schedule 1 to facilitate groundbreaking research into depression and PTSD therapies.
The Royal College of Psychiatrists urges the UK government to reclassify MDMA and psilocybin from Schedule 1 to facilitate groundbreaking research into depression and PTSD therapies.
A new study suggests that psilocybin, the active compound in magic mushrooms, may significantly extend lifespan in mice, opening exciting possibilities for human longevity research.